CL2015001689A1 - Parvovirus 5a porcino, métodos de uso y vacuna - Google Patents

Parvovirus 5a porcino, métodos de uso y vacuna

Info

Publication number
CL2015001689A1
CL2015001689A1 CL2015001689A CL2015001689A CL2015001689A1 CL 2015001689 A1 CL2015001689 A1 CL 2015001689A1 CL 2015001689 A CL2015001689 A CL 2015001689A CL 2015001689 A CL2015001689 A CL 2015001689A CL 2015001689 A1 CL2015001689 A1 CL 2015001689A1
Authority
CL
Chile
Prior art keywords
parvovirus
vaccine
pig
methods
Prior art date
Application number
CL2015001689A
Other languages
English (en)
Inventor
Eric Martin Vaughn
Dianna M Murphy Jordan
Arun V Iyer
Abby Rae Patterson
Michael B Roof
Joseph Gilbert Victoria
Callie Ann Visek
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50931160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of CL2015001689A1 publication Critical patent/CL2015001689A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2015001689A 2012-12-17 2015-06-16 Parvovirus 5a porcino, métodos de uso y vacuna CL2015001689A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738110P 2012-12-17 2012-12-17
US13/796,621 US20140170180A1 (en) 2012-12-17 2013-03-12 Porcine parvovirus 5a, methods of use and vaccine

Publications (1)

Publication Number Publication Date
CL2015001689A1 true CL2015001689A1 (es) 2016-09-09

Family

ID=50931160

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001689A CL2015001689A1 (es) 2012-12-17 2015-06-16 Parvovirus 5a porcino, métodos de uso y vacuna

Country Status (16)

Country Link
US (2) US20140170180A1 (es)
EP (1) EP2931741B1 (es)
AR (1) AR094725A1 (es)
AU (1) AU2014203571B2 (es)
CA (1) CA2894708A1 (es)
CL (1) CL2015001689A1 (es)
CO (1) CO7461133A2 (es)
DK (1) DK2931741T3 (es)
EA (1) EA031278B1 (es)
ES (1) ES2689515T3 (es)
MX (1) MX2015007723A (es)
PH (1) PH12015501378B1 (es)
SG (1) SG11201504805PA (es)
TW (2) TW201920662A (es)
UA (1) UA117467C2 (es)
WO (1) WO2014099669A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
KR20160144383A (ko) * 2014-04-17 2016-12-16 인터벳 인터내셔널 비.브이. 돼지 파르보바이러스
WO2016210097A1 (en) * 2015-06-23 2016-12-29 The Trustees Of Columbia University In The City Of New York Novel equine parvovirus and uses thereof
DK3534939T3 (da) 2016-11-03 2023-04-24 Boehringer Ingelheim Vetmedica Gmbh Vaccine mod porcin parvovirus og porcin reproduktions- og respirationssyndromvirus og fremgangsmåder til fremstilling deraf
MX2019005137A (es) 2016-11-03 2019-06-20 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra parvovirus porcino.
KR102243368B1 (ko) * 2019-04-17 2021-04-23 대한민국 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도
CN111454969B (zh) * 2019-09-02 2022-08-26 西北农林科技大学 带有双标签猪细小病毒全长感染性克隆制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0117767A1 (en) 1983-01-07 1984-09-05 Mgi Pharma, Inc. Production of parvovirus subunit vaccines
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
WO1998011244A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof
US20030049647A1 (en) * 2001-02-22 2003-03-13 Bassil Dahiyat Use of nucleic acid libraries to create toxicological profiles
EP2504357B1 (en) 2009-11-23 2017-08-02 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
KR20160144383A (ko) 2014-04-17 2016-12-16 인터벳 인터내셔널 비.브이. 돼지 파르보바이러스
DK3233890T3 (en) 2014-12-19 2019-04-15 Intervet Int Bv PESTIVIRUS
US9920302B2 (en) 2015-08-31 2018-03-20 Boehringer Ingelheim Vetmedica Gmbh Pestivirus vaccines for congenital tremors
MX2019005137A (es) 2016-11-03 2019-06-20 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra parvovirus porcino.

Also Published As

Publication number Publication date
US20150246113A1 (en) 2015-09-03
AR094725A1 (es) 2015-08-26
CO7461133A2 (es) 2015-11-30
TW201920662A (zh) 2019-06-01
US20140170180A1 (en) 2014-06-19
PH12015501378A1 (en) 2015-09-02
ES2689515T3 (es) 2018-11-14
TW201437369A (zh) 2014-10-01
EA031278B1 (ru) 2018-12-28
AU2014203571A1 (en) 2015-06-11
US9833507B2 (en) 2017-12-05
AU2014203571B2 (en) 2017-09-28
EP2931741B1 (en) 2018-07-25
DK2931741T3 (en) 2018-10-22
EP2931741A1 (en) 2015-10-21
TWI656213B (zh) 2019-04-11
SG11201504805PA (en) 2015-07-30
CA2894708A1 (en) 2014-06-26
UA117467C2 (uk) 2018-08-10
EA201500643A1 (ru) 2015-12-30
PH12015501378B1 (en) 2015-09-02
WO2014099669A1 (en) 2014-06-26
MX2015007723A (es) 2015-09-23

Similar Documents

Publication Publication Date Title
CL2015000640A1 (es) Variantes de hppd y métodos de uso
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
BR112014010175A2 (pt) unidades de filtro, componentes e recursos destas e métodos de uso e construção
CL2015001689A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112015006198A2 (pt) conjunto de cadeira
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112014033077A2 (pt) combinação de vacina.
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
CO6940375A2 (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
SMT201700046B (it) Micobatterio ricombinante come vaccino
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
BR112014005406A2 (pt) composição de vacina e respectivo uso
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
BR112015007217A2 (pt) compostos e usos do composto
DK3062824T3 (da) Telomerase-kodende dna-vaccine
BR112014020372A8 (pt) n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo
BR112014000773A2 (pt) composições de nicotinamida e uso terapêutico das mesmas
BR112015002456A2 (pt) conduto flexível submarino , processo de preparação do conduto flexível submarino, uso de um conduto flexível submarino e uso de um polietileno
DK2805954T3 (da) 7-substitueret hanfangichin b-derivat, og fremstillingsfremgangsmåde og anvendelse deraf